3-Deacetoxy-7-(alpha-amino-1-cyclohexenylacetamido) cephalosporanic acid (SCE-100), a new semisynthetic cephalosporin. II. Comparative in vivo antibacterial activities of SCE-100 and cephalexin (CEX).
The protective activity of 3-deacetoxy-7-(alpha-amino-1-cyclohexenylacetamido) cephalosporanic acid (SCE-100) against experimental intraperitoneal infections in mice caused by several strains of Gram-positive and Gram-negative organisms, including penicillin resistant strains, was compared with that of cephalexin (CEX). Comparable protective effects by oral administration of SCE-100 and CEX were observed in mice infected with Gram-positive organisms, while in mice infected with Gram-negative organisms SCE-100 was less active than CEX. SCE-100 showed a protective effect in infections of mice with either penicillin G-resistant Staphylococcus aureus or ampicillin-resistant Escherichia coli. The oral ED50 of SCE-100 was similar to or slightly larger than the subcutaneous value.
D000284:Administration, Oral; D000667:Ampicillin / Q000494:pharmacology; D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy* / Q000517:prevention & control; D002506:Cephalexin / Q000627:therapeutic use*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D010403:Penicillin Resistance; D013997:Time Factors
D002511:Cephalosporins; D000667:Ampicillin; D002506:Cephalexin